A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

Inclusion criteria

• . Has untreated (eg, no prior investigational therapies, chemotherapy, or radiation therapy), locally advanced or metastatic adenocarcinoma of the head, neck, uncinate process, or tail of the pancreas with a local or metastatic lesion that is amenable to biopsy before and after treatment. (Whenever possible, the before and after treatment biopsies should be from the same lesion.)
• . Is able and willing to undergo tumor biopsy before and after treatment. (A pretreatment biopsy may not be needed if tissue is available from a biopsy conducted within 28 days prior to screening that is adequate for the study assessments.)
• . Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• . Is 18 to 75 years of age, inclusive
• . Has adequate organ function within 28 days of treatment initiation
• . For participants with exposure to prior agents associated with decreased left ventricular ejection fraction (LVEF) (e.g. anthracyclines), or if clinically warranted, a documented LVEF \> 45% using a standard echocardiogram (ECHO) or multigated acquisition (MUGA) scan test at Screening or within 60 days prior to Cycle 1 Day 1. ECHO or MUGA testing for other participants without relevant medical history or clinical symptoms can be performed if feasible.
• . Has oxygen saturation ≥ 92% on room air.
• . Is able to take an oral medication.

Exclusion criteria